Download PDFPDF

Population pharmacokinetics of high dose ibuprofen in cystic fibrosis
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Beware of liver disease for High dose ibuprofen in cystic fibrosis

    Dear Editor

    We read also with interest the response to " High dose ibuprofen in cystic fibrosis"[1] as "Beware of liver disease" from Mordy R Muorah, and his question about if similar exclusion criteria than Konstan MW applied in his research,[2] we also did. Exclusion criteria were needed for oral steroids, or other NSAIDs, known as hypersensitivity to NSAIDs, liver disease, peptic ulcera, or cardiac, renal, hem...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    High dose ibuprofen in cystic fibrosis: Beware of liver disease
    • Mordi R Muorah, Paediatric Hepatology SHO
    • Other Contributors:
      • Rupert Hinds and Nedim Hadzic

    Dear Editor

    We read with interest the study on the use of high dose ibuprofen in cystic fibrosis (CF) by Arranz et al.[1] Whilst we appreciate the possible beneficial effects of high dose ibuprofen on lung function, we are concerned that its non-critical use could be associated with some risks, despite monitoring of drug levels.

    The authors quote an earlier report showing that ibuprofen can be u...

    Show More
    Conflict of Interest:
    None declared.